Hui Wang, PhD

Gilead Sciences Inc.
Foster City, California, United States

Disclosure(s): Gilead Sciences, Inc.: Employee, Stocks/Bonds (Public Company)

Presentation(s):

• 154 - Pharmacokinetics and Safety of GS-1720 Following Multiple Ascending Doses in a Phase 1a Study in People Without HIV-1

  Thursday, October 17, 2024
  1:45 PM – 2:00 PM US PT

• 155 - Long-Acting Subcutaneous Lenacapavir in People with Multi-Drug Resistant HIV-1: 3-Year Results of the CAPELLA Study

  Thursday, October 17, 2024
  2:00 PM – 2:15 PM US PT